Status:
TERMINATED
LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus
Lead Sponsor:
Sanofi
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
40-65 years
Phase:
PHASE4
Brief Summary
The rationale of the study is to determine: * the first dose and the titration of basal insulin * the exact daily time administration of basal insulin in poorly controlled type II diabetic patients.
Eligibility Criteria
Inclusion
- Type 2 Diabetes Mellitus
- Insufficient combined oral antidiabetic treatment (biguanide + sulfonylurea)
- BMI \>25 kg/m2 , \<30 kg/m2
- HbA1c value \>7.0%, \<9.0% within one month
Exclusion
- Type 1 Diabetes Mellitus
- Known malignancy
- Drug or alcohol abuse
- Severe liver disease
- Renal failure (se Creatinine \> 150 micro mol/l)
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00349986
Start Date
September 1 2006
Last Update
December 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Budapest, Hungary